Clinical Trial Update: A comparatiVe Study on Efficacy and Safety of Lipegfilgrastim in Comparison to Pegfilgrastim in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing lipegfilgrastim to pegfilgrastim in elderly patients with aggressive B-cell non-Hodgkin lymphoma at high risk of R-CHOP-21–induced neu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggressive B-cell Non-hodgkin Lymphoma

Drugs mentioned

• Lipegfilgrastim (lipegfilgrastim)
• Pegfilgrastim (pegfilgrastim)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-21-induced Neutropenia | Phase 3 | Status: COMPLETED